Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 54, Issue 5, 2012, Pages 685-689

  Kamperidis, N ^a   Goodhand, J R ^a   Chowdhury, F A ^a   Koodun, Y ^a   Direzke, N C ^a   Naik, S ^a   Sanderson, I R ^a   Croft, N M ^a   Langmead, F L ^a   Irving, P M ^b   Rampton, D S ^a   Lindsay, J O ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

adherence; adolescents; inflammatory bowel disease; thiopurine metabolite levels; thiopurines

Indexed keywords

MERCAPTOPURINE;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SOCIAL ISOLATION; TREATMENT REFUSAL; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADOLESCENT; COLITIS, ULCERATIVE; CONFIDENCE INTERVALS; CROHN DISEASE; FEMALE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859962805     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182475e71     Document Type: Article

References (11)

1. Jackson CA, Clatworthy J, Robinson A, et al. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010;105:525-39.
2. Goodhand JR, Hedin CH, Croft NM, et al. Adolescents with IBD: the importance of structured transition care. J Crohns Colitis 2011;5: 509-19.
3. Hait EJ, Barendse RM, Arnold JH, et al. Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. J Pediatr Gastroenterol Nutr 2009;48:61-5.
4. Haines ML, Ajlouni Y, Irving PM, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:1301-7.
5. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007;26:217-25. (Pubitemid 46985496)
6. Bloomfeld RS, Onken JE. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther 2003;17:69-73. (Pubitemid 36140436)
7. ACORN. www.caci.co.uk/acorn-classification.aspx. Last accessed February 1, 2011.
8. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
9. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(suppl A):5-36.
10. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:973-83.
11. Ediger JP,Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007;102:1417-26. (Pubitemid 46976288)